| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 636.19 | 4.0% | 14.9% |
| Total Income | 639.06 | 3.6% | 15.3% |
| Expenditure | 612.41 | 1.8% | 12.9% |
| PBT | 26.65 | 61.5% | 114.2% |
| Net Profit | 14.56 | 68.0% | 58.8% |
| OPM | 12.40% | 5.51pp | 2.76pp |
| NPM | 2.28% | 4.57pp | 0.63pp |
| EPS | 1.10 | 66.0% | 66.7% |
Growth on track, but Q2 execution softer; margin path intact
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Met revenue guidance (14.9% YoY), missed Flavour (₹72 Cr vs ₹95-96 Cr implied), missed margins (13% vs 13.4% prior), delayed Vanvate (Q4 not Q3).
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Revenue growth on track (14.9% YoY), but Q2 execution softened: Flavour below run rate (₹72 Cr vs ₹90 Cr sustainable), OPM compressed 120bp QoQ to 12.4%, PAT crashed 68% QoQ due to interest and depreciation load. Management's 12-13% FY27+ growth guidance remains intact with 15% margin target, but near-term execution risk and high debt (₹911 Cr) require proof of margin recovery in H2.
₹636.2 Cr
Revenue · +14.9% YoY₹14.6 Cr
Reported PAT · +58.8% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Flavour segment reported strong 47% growth in H1
OVERSTATED₹184 Cr H1, but includes ₹15 Cr Q1 inventory pull-forward; Q2 ₹72 Cr vs ₹90 Cr sustainable run rate
EBITDA margins improving to 13% with profitability protected
OVERSTATEDH1 EBITDA margin 13% (YoY improvement), but Q2 margin compressed to 12.4% vs Q1 ~13.6%
FY27 double-digit revenue growth trajectory sustained
METQ2 revenue ₹636.2 Cr up 14.9% YoY, H1 ₹1,299 Cr up 14% YoY. Achieved
Flavour normalizing to ₹95-96 Cr/Qtr post-Q1 inventory pull-forward
MISSQ2 delivered ₹72 Cr, management now calls ₹90 Cr the 'sustainable run rate' and 20% growth nominal
Vanvate operational by Q3 FY27
MISSFirst factory now expected Q4 FY27, second factory Q4 FY28. Delayed one quarter
Earnings quality
What changed since the last call
Flavour normalized guidance softened
DowngradePrior: ₹95-96 Cr/Qtr (vs ₹112 Cr Q1 with pull-forward). Q2 actual: ₹72 Cr. Management now frames as '20% sustainable growth' (~₹90 Cr run rate), implying Q2 was below guide
Vanvate operational timeline delayed
DowngradePrior: Q3 FY27 (now 3 months away). Updated: Q4 FY27 (one quarter slip). Second factory moves to Q4 FY28
EBITDA margin path articulated more explicitly
NeutralPrior: '13.4% if sustained'. Current: 13% near-term, 15% target in 12-18 months. Similar ambition, clearer milestones
Debt reduction deferred but still on horizon
DowngradePrior: ₹25 Cr/qtr from Q3 onwards. Current: Delayed to post-March 2027 as inventory unwind completes. Still ₹911 Cr net debt
New geographies showing early traction
UpgradeGermany, UK, USA now generating first sales in H1; Germany expected to be profitable by year-end. Represents progress vs prior 'investment phase only'
The Q&A
Analysts pressed hard on Flavour sustainability (47% appears anomalous), margin compression (why 13% not 13.4%), ROCE justification (expansion capex has low returns now), and Vanvate timeline. Management stood firm on structural story (12-13% growth path real, margins will recover to 15%, ROCEs subdued near-term but normalizing as scale) but conceded Q2 was below Flavour run rate.
Capex timelines & factories — Abhijit Akella, KIE
AnsweredEurope capex nearly complete, factory operational since May. India Fragrance renewal by Q4 FY27. Vanvate Q4 FY27 and Q4 FY28. Second factory start will transition production from Mulund.
Demand dynamics & pricing — Bharat Gupta, Fair Value Capital
AnsweredFragrance ~4% volume, 5% cost growth (9% total). Flavour 20% sustainable. RFQ ongoing engagement, no large RFQs closed yet. CDCs in Germany, UK, USA generating early revenues; will take 12-18 months to ramp meaningfully.
ROCE & capex returns — Riddhesh Gandhi, Discovery Capital
PartialMature market ROCEs at ~20%; expansion markets subdued due to investment phase. India market is 5% of global; Europe/US are 35x larger. New factories will normalize ROCEs in 2-3 years as scale builds. Expansion is long-haul play (7-8 years to meaningful returns).
Geographic expansion pace — Pranav Tendolkar, Rare Enterprises
AnsweredGermany has first sales, expected profitable by year-end. US/UK in initial ramp (budgeted sales phase). Will take 12-18 months to ramp revenues, then another 12-18 months to scale meaningfully. Base is small but ramp will be rapid once customers locked.
Margin sustainability & Flavour run rate — Jatin Chawla, RTL Investments
AnsweredQ2 below normal due to timing. Sustainable run rate ₹90 Cr/Qtr (20% growth), ₹72 Cr is lower. 13% margins at lower end now; 15% target 12-18 months (assumes inflation stabilizes, EBITDA grows 13-14% YoY while revenue grows 12-13%).
Inventory unwind & insurance — Tanish Jhaveri, FYERS Asset Management
AnsweredPeak inventory Sept 2026; progressively reducing October onwards. Expect normalization by March 2027. Insurance claim to close in FY27 (by March 2027).
Flavour growth sustainability narrative — Bharat Sheth, Quest Investment Managers
Answered40%+ is anomalous. Sustainable is 20% quarterly (~₹90 Cr run rate). H1 had one-off inventory from customers building safety stock; this will not repeat. Underlying demand remains strong.
CDC investment strategy & market sizing — Raghuram Kuchi, Bestpals Research
AnsweredEurope+US fragrance market USD 24 Bn (India 5% of global scale). Small brands gaining via direct-to-consumer. Keva competes on innovation + cost advantage. Market has USD 10 Bn formulation opportunity. 12% growth sustainable over 3-5 years; ROCEs will normalize as scale builds.
FTA impact & standalone margin compression — Praveen Agarwal, Individual Investor
PartialFTA unlikely to be material (low duties on finished products both ways). Standalone margins depressed due to fire incident impact on factory operations; moved to subsidiary structure. Once consolidated back to direct operations next year, margins will restore.
Guidance
FY27: double-digit growth (12-13% now quantified)
HighReaffirmed after achieving 14.9% Q2 YoY, 14% H1 YoY. Fragrance 11.9%, Flavour ~20% underlying (reported 47% includes inventory). Base case intact
Next 2-3 years: 12-13% growth annually
MediumAssumes macro stabilization, continued new geography contributions, Flavour sustained 20% growth. Contingent on inflation moderation and demand consistency
Current EBITDA margin: 13% (H1 actual)
MediumQ2 came in at 12.4%, below prior 13.4% implied. Management frames as 'lower end of range'; expects recovery as EBITDA growth (13-14%) outpaces revenue growth (12-13%)
EBITDA margin target: 15% (within 12-18 months)
MediumRequires operating leverage as revenue grows and depreciation step from new capex rolls through. Assumes inflation stabilizes and CDC fixed costs leveraged across higher base
Near-term margin path: 13-14% range (next 2-3 years)
MediumBlends improving EBITDA from higher sales with rising depreciation from capex; expects margins to slowly expand as CDCs turn profitable and leverage improves
FY27 capex: ₹30-35 Cr remaining (₹140 Cr full-year on track)
HighEurope capex largely done (May 2026 operational), India Fragrance factory by Q4 FY27, Vanvate Q4. Incremental spend declining
FY28 capex: ₹75-80 Cr (Vanvate phase 2, India Flavour potential)
MediumManagement hinted at second Vanvate factory (operational Q4 FY28) and potential Flavour facility in India. Maintenance capex ~₹15 Cr ongoing
Total capex plan: ~₹140 Cr (FY27-28 cumulative)
HighOriginal guidance still holds; execution on track, though Vanvate delayed 1 quarter (Q3 → Q4 FY27)
Risks the call surfaced
Macro & demand volatility
MediumMiddle East instability, US election uncertainty, raw material volatility could delay demand recovery expected in H2. Inflationary headwinds continue; management cautious but 'very optimistic' if stabilization occurs
Execution risk on geographic expansion
MediumCDCs in Germany, UK, USA, Southeast Asia are early stage; management expects 12-18 months to ramp to meaningful revenue. If customer wins delay or adoption slower, ROCEs remain subdued longer
Working capital cycle & leverage
MediumNet debt ₹911 Cr, interest at peak ₹17.5 Cr/qtr. High inventory held for supply continuity; if sales falter, unwinding delayed and interest burden persists. Debt reduction deferred until post-March 2027
Flavour segment concentration & sustainability
LowH1 Flavour 47% growth includes ₹15 Cr one-time inventory pull-forward from Q1; Q2 normalized to ₹72 Cr. Management clarified sustainable is 20% quarterly (₹90 Cr run rate). If Tier 2 clients remain sluggish, growth may decelerate
Interest & depreciation headwinds on PAT
LowPAT compressed 68% QoQ despite modest revenue decline due to interest at peak (₹17.5 Cr/qtr) + depreciation. New capex will add ~₹5-10 Cr depreciation once operational, further reducing PAT despite EBITDA growth
Management
Score 7/10. Direct and detailed on strategy, though initial framing of Flavour 47% as 'strong growth' glossed over inventory nature. Transparent on challenges (interest costs, fire incident impact, inflation pressures). Clear on long-term vision, vague on near-term execution risks Met revenue growth target (14.9% YoY), missed Flavour normalization (₹72 Cr vs ₹95-96 Cr), missed margin maintenance (13% vs 13.4%), delayed Vanvate (Q4 not Q3). Capex on track. Mixed track record drives confidence down
1 · H2 FY27
Inventory normalization drives working capital release; H2 demand expected strong post-macro stabilization
2 · Q4 FY27
India Fragrance factory capex completion; first Vanvate facility commissioned
3 · FY28
Capex spill-over (₹75-80 Cr), second Vanvate facility, CDC ramp-up in US/Europe/Southeast Asia toward meaningful revenue
Management's 12-13% FY27+ growth guidance remains intact with 15% margin target, but near-term execution risk and high debt (₹911 Cr) require proof of margin recovery in H2.
Growth Intact, But the Margin Compression and Debt Drag Are Real
Revenue growth met guidance at 14.9% YoY, but operating margins compressed 120 basis points quarter-on-quarter and net profit crashed 68% QoQ. The call reveals why — and why near-term execution matters more than the headline.
₹14.6 Cr
-68% QoQ, 2.3% margin
₹168 Cr
+33% YoY, 13% margin
₹17.5 Cr
Peak level; net debt ₹911 Cr
S H Kelkar delivered the revenue promise — ₹636.2 Cr, up 14.9% year-on-year, exactly on the double-digit growth track it guided. But the quarter is a masterclass in why looking below the headline profit line matters. Net profit fell 68% sequentially despite a revenue decline of only 4%. EBITDA grew 33% year-on-year, a strong signal of operational leverage. Yet the PAT print tells a different story: interest costs at peak, depreciation rising, working capital locked in elevated inventory, and the mathematical reality of a ₹911 Cr net debt load sitting on a business with a ₹14.6 Cr quarterly net profit. The growth is real. The margin compression and debt drag are also real.
Where Q2 really went
Net profit is being compressed by three structural forces: (1) Interest on the ₹911 Cr net debt is running at ₹17.5 Cr per quarter, a peak level the CFO himself flagged. (2) Depreciation is rising — now ~₹36–38 Cr quarterly — as new capex from the geometric expansion (Europe factory operational since May, Vanvate coming Q4, India Fragrance renewal) flows through P&L. (3) Working capital is locked: the company built inventory deliberately into September (described as 'peak for the year') to secure supply continuity. Until that unwinds through March 2027, cash will remain tied up. The operating business (EBITDA up 33% YoY) is doing its job. The capital structure is not yet doing its.
Management's claims vs. what holds up
Flavour segment 47% growth in H1
₹184 Cr H1, but includes ₹15 Cr Q1 inventory pull-forward. Q2 actual ₹72 Cr vs ₹90 Cr sustainable run rate (20% growth, not 47%).
Overstated
EBITDA margin stable at 13% with improvement trajectory
H1 EBITDA margin 13% (YoY improvement yes), but Q2 compressed to 12.4% from estimated 13.6% Q1. That is a 120bp QoQ deterioration.
Selective framing
FY27 double-digit revenue growth on track
Q2 delivered 14.9% YoY. H1 tracked 14% YoY. Guidance for 12–13% range intact.
Supported
Flavour normalizing to ₹95–96 Cr/Qtr post-Q1 inventory
Q2 actual ₹72 Cr. Management now describes ₹90 Cr as the 'sustainable run rate' and 20% growth as the underlying driver, not ₹95–96 Cr.
Contradicted (downgrade)
Vanvate operational by Q3 FY27
Revised to Q4 FY27 (one quarter slip). Second factory moved to Q4 FY28.
Contradicted (delay)
The Flavour narrative is the clearest signal of selective transparency. When analysts pressed hard on why 47% growth looked anomalous, management clarified: one-time customer inventory build of ₹15 Cr in Q1 inflated the half-year print. The actual run rate is ₹90 Cr per quarter, which implies 20% growth year-on-year, not 40%+. Management was not wrong, but it let that headline sit unanswered until challenged. Similarly, the margin story went unstated — that Q2 saw a 120-basis-point sequential compression despite near-flat revenue is not a feature management led with.
What changed on this call
Flavour normalization target softened: ₹95–96 Cr/Qtr → ₹90 Cr sustainable run rate (20% growth)
Vanvate operational: Q3 FY27 → Q4 FY27 (one quarter delay); second factory Q4 FY28
New geographies showing traction: Germany first sales, expected profitable by year-end FY27; US/UK/Southeast Asia in budgeted ramp phase
Debt reduction timeline: Deferred to post-March 2027 as inventory unwind completes (was ₹25 Cr/Qtr from Q3 originally)
EBITDA margin target articulated: 15% within 12–18 months (vs. vague '13.4% if sustained' prior); 12–13% revenue growth + fixed-cost deleveraging path named
The bull-bear ledger
Revenue growth delivered on guidance (14.9% YoY); Fragrance broad-based at 11.9%, new geographies contributing
EBITDA growth strong (33% YoY) signals operating leverage real; capex on track (₹140 Cr FY27)
Long-term margin story articulated: 15% EBITDA target in 12–18 months is credible if 12–13% revenue growth holds and capex phase ends
Q2 margin compression (120bp QoQ) despite growth signals execution pressure near-term
PAT crashed 68% QoQ; interest at peak (₹17.5 Cr/Qtr), depreciation rising. Leverage burden real and will persist through H2 FY27
Flavour guidance miss (₹72 Cr Q2 vs ₹95–96 Cr implied) and Vanvate delay (Q3 → Q4) are execution signals; track record this quarter: C-grade (hit revenue, missed Flavour, missed margins, missed Vanvate timing)
Working capital cycle risk: ₹911 Cr net debt, inventory peak Sept, normalization to March 2027. If demand falters H2, unwinding delayed and interest burden persists
New geography ROCEs subdued during investment phase (2–3 years); expansion capex returns are back-loaded, not immediately accretive
Risks, ranked by how much they should concern a holder
Macro slowdown delays H2 demand recovery
Medium-HighManagement expects inventory normalization to drive working capital release and Q3–Q4 demand lift post-macro stabilization (MD cited Middle East geopolitics and US elections as key watch items). If macro darkens, that release is delayed and interest burden persists longer.
Working capital cycle extends beyond March 2027
Medium-HighPeak inventory Sept, planned unwind through March. If sales falter H2, unwind delayed. ₹911 Cr net debt at ₹17.5 Cr/Qtr interest means every quarter of delay costs ₹17.5 Cr in cash flow and suppresses PAT.
New geography ramp slower than guided (12–18 months to meaningful revenue)
MediumEurope capex complete, Germany first sales and expected profitable by year-end. But Germany, US, UK are all early-stage; customer wins pipeline not yet public. If adoption slower or larger customer RFQs don't close, ROCEs stay low longer.
Interest costs remain elevated past H2 FY27
MediumCFO explicitly flagged ₹17.5 Cr/Qtr as peak. Debt reduction deferred to post-March 2027. Even with rate stabilization, near-term interest burden keeps PAT suppressed despite EBITDA growth. No relief until debt actually reduces.
Flavour demand Tier 2 client softness spreads to Tier 1
Low-MediumDomestic Fragrance Flavour grew only 9% this quarter (Tier 2 muted). Flavour ₹90 Cr sustainable run rate assumes continued 20% international growth. If domestic weakness spreads, Flavour guidance faces downside risk.
How the street is positioned
Price and trend. SHK is at ₹132.86 (as of 5 November 2026), down 63.39% from its all-time high of ₹362.9. The stock is trading below its 50-day SMA (₹139.07) and 200-day SMA (₹141.98), but just above the 20-day SMA (₹132.12). RSI stands at 48.6, neutral. The stock has recovered 18.65% from its 52-week low but remains well below prior highs, signalling institutional risk-off positioning on the back of execution concerns and leverage burden.
Ownership flows. Foreign Institutional Investors (FII) have been trimming: down 1.50 percentage points quarter-on-quarter to 5.92% in Q1 FY27 (from 7.42% in Q4 FY26). Domestic Institutional Investors (DII) have added modestly, up 0.83pp to 6.01%. This suggests foreign money is de-risking amid leverage and execution questions, while domestic money remains cautious but holding. Promoter stake is stable at 54.87%.
Insider and block activity. No notable promoter or insider selling near the highs. The bulk/block deals noted (July 2026) were mutual fund (Elixir) trades at ₹166.61/₹166.30, not strategic moves. This is consistent with the street's view that the stock decline reflects fundamental concerns (margin pressure, debt load, execution delays) rather than distressed promoter or insider selling.
Valuation context. At ₹132.86, the stock sits in a no-man's-land: not so low that it screams value, not high enough to attract the growth premium it commanded at ₹362.9. The near-63% drawdown suggests the market has repriced execution risk (Flavour miss, Vanvate delay, margin compression) into a lower multiple. FII outflows confirm the street is waiting for proof of margin recovery and debt reduction before re-engaging. The honest read: the market is right to be cautious until H2 FY27 and March 2027 inventory normalization deliver.
The debate
What to watch next
1 · Inventory normalization and working capital release
Peak was September 2026. Management guided for normalization by March 2027. If October–Q3 FY27 sees inventory actually reducing and cash releasing, the working capital risk thesis weakens. If inventory holds or rises, interest burden will persist and the bear case gains weight.
2 · Q3 FY27 margin recovery (OPM back above 13%)
Q2 OPM fell to 12.4% from estimated 13.6% Q1. If Q3 margin bounces back toward 13%+, it signals Q2 was execution-driven softness, not structural deterioration. If margins stay 12–12.5%, it confirms near-term headwinds are stickier and the path to 15% is slower.
3 · New geography (Germany, US, UK) revenue ramp and customer wins
Q3–Q4 FY27 will tell if 12–18 month ramp assumption holds. Germany expected profitable by year-end; first customer revenue flow visible. If ramp is on pace and customer wins announced, execution confidence re-establishes. Delays here suggest aggressive guidance and lower near-term accretion.
What to track from here
Forget reported PAT for the next two quarters. Track EBITDA growth and EBITDA margin. EBITDA up 33% YoY is the real signal that operations are working. Once inventory normalizes (March 2027) and debt reduction begins, the leverage burden will ease and PAT will re-accelerate. But the through line for the next 6 months is whether EBITDA growth holds at 13–14% annually while the interest and depreciation drag gradually unwind.
S H Kelkar has delivered on revenue growth — 14.9% YoY is real and the long-term story remains structurally sound. But this quarter exposed a gap between the headline and the reality: margin compression, interest burden, Flavour guidance miss, and Vanvate delay. These are not fatal flaws, but they are not invisible either. The stock's 63% drawdown from its all-time high and FII outflows suggest the market is right to demand proof — not promise — of margin recovery and debt discipline. Hold for the structural story, but do not ignore the near-term headwinds. The number to track is EBITDA margin trajectory and working capital release starting March 2027. That will reset confidence.